Characteristics, Management, and Outcomes of Community-Acquired Pneumonia Due to Human Rhinovirus—A Retrospective Study

Table 2

Management of patients.

Variable	All patients; N = 106	ICU admission; N = 16	No ICU admission; N = 90	value
Mechanical ventilation, N (%)	9 (8.7)	9 (69.2)	0 (0)	<0.001
Vasopressors, N (%)	6 (5.7)	6 (37.5)	0 (0)	<0.001
Use of steroids, N (%)	58 (54.7)	10 (62.5)	48 (53.3)	0.50
Initial daily dose (mg of prednisone or equivalent), median (Q1, Q3)	120 (40, 120)	50 (40, 105)	120 (50, 120)	0.02
Antimicrobial therapy, N (%)
No initial antibiotic	7 (6.7)	0 (0)	7 (8)	0.60
Fluoroquinolones	4 (3.8)	0 (0)	4 (4.5)	1.0
Beta lactam alone	13 (12.3)	1 (6.3)	12 (13.3)	0.69
Antipseudomonal beta lactam	7 (6.6)	2 (12.5)	5 (5.6)	0.28
Beta lactam + azithromycin	43 (40.6)	3 (18.8)	40 (44.4)	0.06
Antipseudomonal beta lactam + azithromycin	30 (28.3)	10 (62.5)	20 (22.2)	0.002
Oseltamivir, N (%)	73/106 (68.9)	10 (62.5)	63/90 (70)	0.55

ICU: intensive care unit, Q1: first quartile, and Q3: third quartile.